Tokyo, March 31 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000057577) titled 'A retrospective clinical study of mortality according to hemoglobin levels and administration of calcimimetics and erythropoietin stimulating agents in dialysis patients' on March 31.
Study Type:
Observational
Primary Sponsor:
Institute - Social medical corporation Kawashimakai Kawashima Hospital
Condition:
Condition - Patients with end-stage kidney disease undergoing hemodialysis and online hemodiafiltration
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - A propensity score matching model and adjusted Cox regression analysis is used in a retrospective 2-year observational study. The effects of mortality in patients within target Hb range grouping by users and non-users with ESAs and/or calcimimetics . In addition, chi-square tests is performed to assess the 1-year and 2-year mortality on patients whose Hb values are within and outside the target range grouping by users and non-users with ESAs and/or calcimimetics.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 20
years-old
12.9g/dL
Target Size - 738
Recruitment Status:
Recruitment status - Terminated
Date of protocol fixation - 2025 Year 03 Month 08 Day
Date of IRB - 2025 Year 04 Month 08 Day
Anticipated trial start date - 2025 Year 04 Month 15 Day
Last follow-up date - 2025 Year 08 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065284
Disclaimer: Curated by HT Syndication.
